Swissdamed Devices Database Will Mirror Eudamed

Medical device database for Switzerland fully live in 2023

15 Sep 2022

Outside the EU and no longer enjoying an MRA with the bloc, Switzerland has had to develop its own medical device database, work on which will continue into next year.

Among the many concerns of the Swiss medical devices industry, on witnessing the ending of the two-decades-old Swiss-EU mutual recognition agreement (MRA), was that local companies would no longer have access to Eudamed, the in-development EU medical devices database.

The Swiss Agency for Therapeutic Products, Swissmedic, set about building its own database and this week reported progress towards that goal. It also confirmed that the new national database, “swissdamed”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Commission’s Flora Giorgio Says Simplification And Safety Are Key In Evolving EU Regs

27 May 2025

• By Amanda Maxwell

Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

22 May 2025

• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

20 May 2025

• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.